PMID-sentid	Pub_year	Sent_text	compound_name	comp_offset	prot_official_name	organism	prot_offset
10825654-4	2000	The most potent of inhibition of SSAO was observed by imipramine, followed by maprotiline, zimeldine and nomifensine.	Zimeldine	91-100	amine oxidase copper containing 2	Homo sapiens	33-37
17175203-5	2007	All compounds tested inhibited Na(V)1.7 in a state- and use-dependent manner, with affinities for the inactivated state ranging from 0.24 micromol/L for amitriptyline to 11.6 micromol/L for zimelidine.	Zimeldine	190-200	neuron navigator 1	Homo sapiens	31-37
17175203-8	2007	By contrast, fluoxetine, paroxetine, mianserine, and zimelidine had IC(50)s for Na(V)1.7 outside their therapeutic concentration ranges and generally were not efficacious against post-herpetic neuralgia or diabetic neuropathy.	Zimeldine	53-63	neuron navigator 1	Homo sapiens	80-86
16736239-6	2006	The results suggest the involvement of 5-HT(2C) and 5-HT(1A) receptors in the anticonvulsant effects of zimelidine and possibly other SSRIs in stress.	Zimeldine	104-114	5-hydroxytryptamine (serotonin) receptor 2C	Mus musculus	39-46
10808050-6	2000	Chronic (14 days) administration of the antidepressant drugs desipramine or zimelidine transforms alpha(2)-adrenergic receptor-dependent decreases in TNF levels to increases in levels of TNF in the locus coeruleus.	Zimeldine	76-86	tumor necrosis factor	Rattus norvegicus	150-153
10808050-6	2000	Chronic (14 days) administration of the antidepressant drugs desipramine or zimelidine transforms alpha(2)-adrenergic receptor-dependent decreases in TNF levels to increases in levels of TNF in the locus coeruleus.	Zimeldine	76-86	tumor necrosis factor	Rattus norvegicus	187-190
15219273-0	2004	Synthesis and evaluation of radiolabeled analogs of the antidepressant drug zimelidine as potential SPECT-ligands for the serotonin transporter.	Zimeldine	76-86	solute carrier family 6 member 4	Homo sapiens	122-143
11303058-5	2001	Superfusion of hippocampal slices obtained from rats chronically administered the antidepressant drug zimelidine demonstrates that TNF-mediated inhibition of [(3)H]NE release is transformed, such that [(3)H]NE release is potentiated in the presence of TNF, an effect that occurs in association with alpha(2)-adrenergic receptor activation.	Zimeldine	102-112	tumor necrosis factor	Rattus norvegicus	131-134
11303058-5	2001	Superfusion of hippocampal slices obtained from rats chronically administered the antidepressant drug zimelidine demonstrates that TNF-mediated inhibition of [(3)H]NE release is transformed, such that [(3)H]NE release is potentiated in the presence of TNF, an effect that occurs in association with alpha(2)-adrenergic receptor activation.	Zimeldine	102-112	tumor necrosis factor	Rattus norvegicus	252-255
9724254-6	1998	min-1), Na+-dependent mechanism that was inhibited by chlorimipramine > imipramine > fluoxetine > desipramine > zimelidine.	Zimeldine	124-134	CD59 molecule (CD59 blood group)	Homo sapiens	0-5
10580379-2	1999	Mouse, rat, dog and monkey brain MAO-B activities were inhibited by zimeldine more potently than MAO-A activity.	Zimeldine	68-77	monoamine oxidase B	Canis lupus familiaris	33-38
1720996-5	1991	Zimelidine treatment of unlesioned animals significantly increased PPT mRNA levels in the neostriatum.	Zimeldine	0-10	tachykinin, precursor 1	Rattus norvegicus	67-70
8842678-10	1996	MAO-A was inhibited by the following drugs (in ascending order of potency) : nortriptyline, amitriptyline, imipramine, maprotiline, zimeldine, nomifensine, and viloxazine.	Zimeldine	132-141	monoamine oxidase A	Mus musculus	0-5
8842678-12	1996	MAO-B was inhibited by the following drugs (in ascending order of potency): nortriptyline, imipramine, maprotiline, amitriptyline, zimeldine, nomifensine, and viloxazine.	Zimeldine	131-140	monoamine oxidase B	Mus musculus	0-5
7633328-1	1995	We have previously reported elevated brain tissue contents of neuropeptide Y-like immunoreactivity (NPY-LI) following 3 weeks of oral treatment with the antidepressants zimelidine and imipramine.	Zimeldine	169-179	neuropeptide Y	Rattus norvegicus	62-76
7633328-1	1995	We have previously reported elevated brain tissue contents of neuropeptide Y-like immunoreactivity (NPY-LI) following 3 weeks of oral treatment with the antidepressants zimelidine and imipramine.	Zimeldine	169-179	neuropeptide Y	Rattus norvegicus	100-103
8395387-5	1993	Administration of tryptophan or zimelidine significantly shortened immobility in the swim test in the TGF alpha male mice.	Zimeldine	32-42	transforming growth factor alpha	Mus musculus	102-111
1358930-4	1992	Somatostatin content was similarly reduced in the hypothalamus, and midbrain and thalamus following repeated administration of zimelidine, another specific serotonin uptake inhibitor.	Zimeldine	127-137	somatostatin	Rattus norvegicus	0-12
8389958-3	1993	Just like the mRNA coding for the precursor of SP (preprotachykinin, PPT), levels of TRH mRNA are increased when serotonin synthesis is inhibited by para-chlorophenylalanine (pCPA) and decreased when serotonin reuptake is blocked by zimelidine.	Zimeldine	233-243	thyrotropin releasing hormone	Homo sapiens	85-88
8389958-5	1993	Levels of TRH mRNA are still decreased after 14 days of zimelidine treatment, a time when levels of PPT mRNA have returned to control values.	Zimeldine	56-66	thyrotropin releasing hormone	Homo sapiens	10-13
8389958-5	1993	Levels of TRH mRNA are still decreased after 14 days of zimelidine treatment, a time when levels of PPT mRNA have returned to control values.	Zimeldine	56-66	tachykinin precursor 1	Homo sapiens	100-103
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	Zimeldine	166-176	5-hydroxytryptamine receptor 1A	Homo sapiens	13-28
8389958-7	1993	Finally, the 5-HT1A receptor agonist 8-hydroxy-2-(di-n-propylamino)tetralin (8-OH-DPAT) induces a transient decrease in levels of PPT mRNA similar to that induced by zimelidine, but does not decrease levels of TRH mRNA even when 10-fold higher doses are administered.	Zimeldine	166-176	tachykinin precursor 1	Homo sapiens	130-133
1535634-5	1992	In the IFN-gamma secretion assay zimeldine, CPP 200, clomipramine and maprotiline all in a concentration-dependent mode reduced the number of IFN-gamma secreting cells while norzimeldine and imipramine did not affect the IFN-gamma secretion.	Zimeldine	33-42	interferon gamma	Rattus norvegicus	7-16
1535634-5	1992	In the IFN-gamma secretion assay zimeldine, CPP 200, clomipramine and maprotiline all in a concentration-dependent mode reduced the number of IFN-gamma secreting cells while norzimeldine and imipramine did not affect the IFN-gamma secretion.	Zimeldine	33-42	interferon gamma	Rattus norvegicus	142-151
1535634-5	1992	In the IFN-gamma secretion assay zimeldine, CPP 200, clomipramine and maprotiline all in a concentration-dependent mode reduced the number of IFN-gamma secreting cells while norzimeldine and imipramine did not affect the IFN-gamma secretion.	Zimeldine	33-42	interferon gamma	Rattus norvegicus	142-151
1535634-7	1992	The action of several drugs on induced T cell secretion of IFN-gamma suggests that the mechanisms for the suppressive effect of zimeldine and norzimeldine on EAN symptoms can be due to an action on myelin T cell autoreactivity.	Zimeldine	128-137	interferon gamma	Rattus norvegicus	59-68
1388278-9	1992	The data indicate that the sleep-waking effects of zimeldine cannot easily be explained by stimulation of 5-HT1A receptors.	Zimeldine	51-60	5-hydroxytryptamine receptor 1A	Rattus norvegicus	106-112
2416297-4	1985	Desipramine hydrochloride, a norepinephrine uptake inhibitor, reduced 5-HIAA as well as MHPG concentrations; zimeldine hydrochloride, a serotonin uptake inhibitor, reduced MHPG as well as 5-HIAA concentrations; and clorgyline, a selective monoamine oxidase type A inhibitor, which might be predicted to most affect 5-HIAA, dramatically reduced MHPG, moderately reduced homovanillic acid, and only modestly reduced 5-HIAA concentrations.	Zimeldine	109-132	monoamine oxidase A	Homo sapiens	239-263
1713119-3	1991	By contrast, raising extracellular 5-HT levels with zimelidine (a 5-HT uptake inhibitor) or clorgyline (a monoamine oxidase inhibitor) resulted in increased levels of PPT mRNA.	Zimeldine	52-62	tachykinin, precursor 1	Rattus norvegicus	167-170
19912792-0	1991	Both zimelidine and clorgyline decrease preprotachykinin mRNA in adult medullary raphe nuclei.	Zimeldine	5-15	tachykinin precursor 1	Homo sapiens	40-56
19912792-7	1991	Both zimelidine and clorgyline decreased levels of PPT mRNA in medullary raphe neurons and SP-LI in the ventral spinal cord.	Zimeldine	5-15	tachykinin precursor 1	Homo sapiens	51-54
2828545-11	1988	Decreasing 5-HT2 function by twice-a-day injection of 5 mg/kg of zimeldine or desipramine (DMI) produced 50% (p less than 0.01) and 56% (p less than 0.01), respectively, reductions in head-twitch behaviour.	Zimeldine	65-74	hypothermia due to alcohol sensitivity 2	Mus musculus	13-16
2483172-8	1988	Upon treatment with zimelidine the tissue levels of the serotonin metabolite 5-hydroxyindoleacetic acid fall by 32% while thyrotropin releasing hormone levels seem to increase 35% and substance P/substance K levels also increase 48 and 72% respectively.	Zimeldine	20-30	thyrotropin releasing hormone	Rattus norvegicus	122-151
2439937-10	1987	In the periaqueductal grey matter, treatment with zimelidine and alaproclate increased the levels of SP-LI and NKA/NKB-LI, while treatment with imipramine increased only the level of NKA/NKB-LI.	Zimeldine	50-60	Natural killer alloreactivity QTL 1	Rattus norvegicus	111-114
2439937-10	1987	In the periaqueductal grey matter, treatment with zimelidine and alaproclate increased the levels of SP-LI and NKA/NKB-LI, while treatment with imipramine increased only the level of NKA/NKB-LI.	Zimeldine	50-60	Natural killer alloreactivity QTL 1	Rattus norvegicus	183-186
2438584-0	1987	Changes in nociception after acute and chronic administration of zimelidine: different effects in the formalin test and the substance P behavioural assay.	Zimeldine	65-75	tachykinin 1	Mus musculus	124-135
2438584-1	1987	The selective inhibitor of the reuptake of 5-hydroxytryptamine (5-HT), zimelidine, was administered intraperitoneally to mice (10 mg/kg) and nociceptive sensitivity was evaluated using the formalin test (20 microliters of 1% formalin, injected subcutaneously) and the assay for substance P (5 ng administered intrathecally).	Zimeldine	71-81	tachykinin 1	Mus musculus	278-289
2438584-2	1987	Zimelidine increased the behavioural response to formalin, but reduced the response to substance P.	Zimeldine	0-10	tachykinin 1	Mus musculus	87-98
2436109-0	1987	Increased sensitivity to intrathecal substance P following chronic administration of zimelidine.	Zimeldine	85-95	tachykinin precursor 1	Homo sapiens	37-48
2436109-1	1987	The behavioural response to intrathecal substance P (SP) was evaluated following acute and chronic administration of the selective serotonin reuptake inhibitor zimelidine.	Zimeldine	160-170	tachykinin precursor 1	Homo sapiens	40-51
2436109-1	1987	The behavioural response to intrathecal substance P (SP) was evaluated following acute and chronic administration of the selective serotonin reuptake inhibitor zimelidine.	Zimeldine	160-170	tachykinin precursor 1	Homo sapiens	53-55
2436109-2	1987	A single dose of zimelidine (10 mg/kg) attenuated the response to SP by approximately 40%, in agreement with previous findings that acute administration of zimelidine reduces nociceptive behaviour.	Zimeldine	17-27	tachykinin precursor 1	Homo sapiens	66-68
2436109-2	1987	A single dose of zimelidine (10 mg/kg) attenuated the response to SP by approximately 40%, in agreement with previous findings that acute administration of zimelidine reduces nociceptive behaviour.	Zimeldine	156-166	tachykinin precursor 1	Homo sapiens	66-68
2436109-3	1987	Twenty-four hours following the withdrawal of long-term treatment with zimelidine (10 mg/kg X 2 daily for 14 days) the behavioural response to SP was increased by 116%.	Zimeldine	71-81	tachykinin precursor 1	Homo sapiens	143-145
2861620-2	1985	None of the other psychotropic agents used in this study similarly affected CSF somatostatin, although zimelidine appeared to increase CSF somatostatin in a small number of patients.	Zimeldine	103-113	colony stimulating factor 2	Homo sapiens	135-138
6237705-4	1984	Repeated oral doses of zimeldine (20 mg kg-1 per day, 14 days) also decreased the head-twitch response and the number of 5-HT2 binding sites and these effects persisted after 48 h withdrawal.	Zimeldine	23-32	hypothermia due to alcohol sensitivity 2	Mus musculus	123-126
6452790-2	1981	At steady-state the active metabolite of zimelidine, norzimelidine, predominated in the CSF by a factor of 7 to 1 over parent drug.	Zimeldine	41-51	colony stimulating factor 2	Homo sapiens	88-91
6230892-3	1983	The results showed zimeldine to be significantly more effective than placebo, both in terms of preventing recurrence (t-test: P less than 0.001) and the withdrawal rate (Cox"s test: P less than 0.01).	Zimeldine	19-28	cytochrome c oxidase subunit 8A	Homo sapiens	170-173
6306711-1	1983	Plasma ACTH levels after oral ingestion of 2 g metyrapone at 24.00 hours in six healthy subjects were higher after pretreatment with zimelidine (300 mg) in comparison to placebo.	Zimeldine	133-143	proopiomelanocortin	Homo sapiens	7-11
6306711-2	1983	Since zimelidine is a relatively selective serotonin reuptake inhibitor its action on hypothalamic-pituitary-adrenal (HPA) activity suggests that serotonin is a potent stimulator of ACTH release.	Zimeldine	6-16	proopiomelanocortin	Homo sapiens	182-186
6971560-2	1981	Chlorimipramine, citalopram, fluoxetine, imipramine and zimelidine potentiated the low dose 5-hydroxytryptophan (5-HTP)-induced increase in prolactin secretion, suggesting inhibition of serotonin (5-HT) uptake by these drugs.	Zimeldine	56-66	prolactin	Rattus norvegicus	140-149
116266-0	1979	Effects of zimelidine, a selective 5-HT uptake inhibitor, on serum prolactin levels in man.	Zimeldine	11-21	prolactin	Homo sapiens	67-76
116266-1	1979	The levels of serum prolactin were studied both after an acute intake of zimelidine and during a treatment period of 3--7 weeks.	Zimeldine	73-83	prolactin	Homo sapiens	20-29